NEI Podcast

Food and beverages interact with certain psychiatric medications to alter their pharmacokinetic properties, resulting in potentially unintended health outcomes. In this podcast episode, Dr. Rajnish Mago describes common food and beverages that interact with psychiatric medication and provides recommendations for avoiding unintended food-drug interactions.

Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe the effects of food on the bioavailability of certain psychotropic medications Discuss current evidence of the brain-gut connection’s impact on mental health
• Describe the effects of vitamin C, caffeine, and grapefruit on the pharmacokinetics of certain psychotropic medications

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by a PharmD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Faculty Interviewer / Author

Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris

Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris

Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris

Faculty Interviewee / Author

Rajnish Mago, MD

Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Travel Expenses: Intas Pharmaceuticals (for Indian Psychiatric Association annual meeting)

Stockholder: Johnson and Johnson

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

Support: This activity is supported solely by the provider, NEI.

Released: May 11, 2020 CME credit expires: May 11, 2023

What is the evidence that exercise is at least as effective as medications for the treatment of mental health disorders, such as depression? Can you share any research findings on the effects of exercise for patients with traumatic brain injury? If you have questions like these, you won't want to miss this episode with psychiatrist and renowed author, Dr. John Ratey!

Best selling author, John J. Ratey, MD, is an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. He has published over 60 peer-reviewed articles, and 11 books published in 17 languages, including the groundbreaking ADD-ADHD “Driven to Distraction” series with Ned Hallowell, MD. With the publication of "Spark-The Revolutionary New Science of Exercise and the Brain," Dr. Ratey has established himself as one of the world's foremost authorities on the brain-fitness connection. His most recent book, “Go Wild” explores how we can achieve optimal physical and mental health by getting in touch with our caveman roots, and how we can “re-wild” our lives. Recognized by his peers as one of the Best Doctors in America since 1997, Dr. Ratey was recently honored by the Massachusetts Psychiatric Society as "Outstanding Psychiatrist of the Year" for advancing the field. Dr. Ratey and his work are frequently profiled in the media, where he’s been featured on ABC, CBS, NBC, PBS and NPR, as well as in The New York Times, Newsweek, The Washington Post, US News and World Report, Men’s Health, and other national publications.

With the recent COVID-19 pandemic, mental health concerns are on the rise. What do we know about the relationship between suicide risk and previous pandemics or natural disasters? How do we distinguish between behavior that seems like appropriate coping during this time and behavior that should raise a red flag? What are some protective factors against suicide, and how can we capitalize on these, especially during this challenging time? Join us, as we interview the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP), Dr. Christine Moutier.

Dr. Moutier knows the impact of suicide firsthand. After losing colleagues to suicide, she dedicated herself to fighting this leading cause of death. Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions.

As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide.

Moutier has authored articles and book chapters for publications such as the Journal of the American Medical Association, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Psychiatric Times, Depression and Anxiety, and Academic Psychiatry.

She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN , and other print and television outlets.

You can follow Dr. Moutier on Twitter at @cmoutierMD.

For more information on the AFSP please visit: afsp.org

Given the recent COVID-19 virus pandemic, how is pediatric anxiety influenced by things like the media, parental attitudes, and the family environment? How effective is telepsychiatry for pediatric patients? If you have these types of questions you won't want to miss this timely and important interview with psychiatrist Dr. Jeffrey Strawn! In this episode, we discuss issues like effective communication strategies for parents during this time, and how to best meet the needs of pediatric patients with anxiety.

Dr. Strawn is an Associate Professor of Psychiatry and Pediatrics at the University of Cincinnati and at Cincinnati Children’s Hospital. He directs the University of Cincinnati Anxiety Disorders Research Program. His ongoing research explores the pathophysiology and psychopharmacology of anxiety disorders, using functional neuroimaging and magnetic resonance spectroscopy. His research further aims to identify early predictors of treatment response in anxiety and to identify which patients may respond best to which specific treatments. In his clinical practice, he works with youth with anxiety disorders and with their parents and families.

Methamphetamine is an extremely serious problem in the United States, and it remains one of the most commonly misused stimulant drugs in the world. There are severe psychological, and medical consequences from methamphetamine misuse and abuse. This poses a particular challenge for clinicians treating patients for mental health conditions that are comorbid with substance use disorder (SUD). This is especially challenging when there are also interactions that can alter or influence psychiatric medications used to treat these patients. Questions such as the following arise: Given the high comorbidity of SUD with ADHD, how often should you check drug screens, and what is the threshold for discontinuing the stimulants if tests come back positive? In this podcast episode, Dr. William Sauve’ addresses these concerns, and much more. He also employs strategies to improve communication with patients about being transparent when it comes to using substances.

Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.

Learning Objectives: After completing this educational activity, you should be better able to:

• Manage the challenges associated with psychiatric treatment of conditions comorbid with substance use disorder
• Integrate psychiatric drug interactions with methamphetamine use
• Assess treatments approaches for conditions associated with long-term use of methamphetamines

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Faculty Interviewer

Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris

Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris

Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris

Faculty Interviewee

William M. Sauvé, MD

Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia

Speakers Bureau: Avanir

Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

Support: This activity is supported solely by the provider, NEI.

Released: June 8, 2020 CME credit expires: June...